Abstracts Archive - Page 2291 of 2425 - ACR Meeting Abstracts

Abstract Number: 1968 • 2012 ACR/ARHP Annual Meeting
The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã2-Ca2+-NFAT Signaling
Chang-Hoon Lee¹, Wan-Hee Yoo², Jin-Jung Choi³, Myong-Joo Hong⁴, Ji-Min Kim⁵ and Sik-Won Choi⁶, ¹Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ²Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ³Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁴Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, ⁶Department of Anatomy and Institute for Skeletal Disease, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea
Background/Purpose: Recently, Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) has been shown to regulate calcium homeostasis in myotrophic lateral sclerosis. Calcium signalingis also important in metabolic bone diseases,…
Abstract Number: 1969 • 2012 ACR/ARHP Annual Meeting
Correction of Vitamin D Insufficiency with the Fixed Daily Combination Strontium Ranelate 2 g/Vitamin D₃ 1000 IU Over 12 Months
René Rizzoli¹, Bess Dawson-Hughes², Jean-Marc Kaufman³, Patrice Fardellone⁴, Maria Luisa Brandi⁵, Bruno Vellas⁶, Julien Collette⁷ and Jean-Yves Reginster⁸, ¹Division of Bone Disease, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ²Jean Mayer United States Department of Agriculture, Human Nutrition Research, Center on Aging, Bone Metabolism Laboratory, Tufts University, Boston, MA, ³Department of Endocrinology, University Hospital of Ghent, Ghent, Belgium, ⁴Service de Rhumatologie, Hôpital Nord, C.H.U. d'Amiens, Amiens, France, ⁵Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy, ⁶CHU La Grave, Toulouse, France, ⁷University of Liege, Labo RIA, CHU Sart Tilman, Liege, Belgium, ⁸Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
Background/Purpose: To assess the efficacy and safety over 1 year of a daily oral administration of the fixed combination of strontium ranelate (SrRan) 2 g/vitamin…
Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Tristan Blackburn¹, Diantha Howard² and Edward S. Leib³, ¹Rheumatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ²Medicine, Vermont Center for Clinical and Translational Science, Burlington, VT, ³Medicine, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…
Abstract Number: 1971 • 2012 ACR/ARHP Annual Meeting
Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use
Kenneth G. Saag¹, Claude-Laurent Benhamou², Tobias De Villiers³, C. Conrad Johnston Jr.⁴, Bente Langdahl⁵, Andrew Denker⁶, Annpey Pong⁶, John P. McGinnis⁶, Elizabeth Rosenberg⁶ and Arthur Santora⁶, ¹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²Centre Hospitalier Régional d'Orléans, Orleans, France, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: While bisphosphonates (BP) have been well studied in long-term trials of up to 4 years' duration, relatively less is known about the immediate consequences…
Abstract Number: 1972 • 2012 ACR/ARHP Annual Meeting
Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis
Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen and Merih Akpinar, Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The aim of this study is to determine the risk of osteoporotic fracture in postmenopausal women with rheumatoid arthritis (RA) and to examine the…
Abstract Number: 1973 • 2012 ACR/ARHP Annual Meeting
Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral Density
Yoshitada Sakai¹, Akira Hashiramoto², Takaichi Okano², Yoshiko Kawasaki³, Nao Shibanuma⁴ and Masahiro Kurosaka⁵, ¹The Center of Rheumatic Diseases/ Division of Rehabilitation Medicine, Kobe University Hospital, Kobe, Japan, ²The Center for Rheumatic Diseases,, Kobe University Hospital, Kobe, Japan, ³The Center of Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, ⁴The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁵Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The osteoporotic fracture in patients with rheumatiod arthritis (RA) is caused by systemic osteoporosis as well as periarticular osteoporosis, On the other hand, the…
Abstract Number: 1974 • 2012 ACR/ARHP Annual Meeting
Incidence of Atypical Femur Fractures Associated with Bisphosphonate Use for Osteoporosis: A Systematic Review of the Literature
John N. Mecchella¹, John A. Batsis², Robin J. Larson³ and Gautham Suresh⁴, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²General Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ⁴Neonatology, Pediatrics, Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Reports of a link between bisphosphonate use in patients with osteoporosis and atypical femoral fractures--those occurring in subtrochanteric or diaphyseal locations--have generated significant concern…
Abstract Number: 1975 • 2012 ACR/ARHP Annual Meeting
Mortality After Fragility Hip Fracture in Middle Aged and Elderly Men and Women in Southern Norway
Andreas P. Diamantopoulos¹, Mari Hoff², Marc C. Hochberg³ and Glenn Haugeberg¹, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St Olavs Hospital, Trondheim, Norway, ³Department of Medicine, University of Maryland, Baltimore, MD
Background/Purpose: The mortality of the fragility hip fracture patients has been reported to be higher compared to the general population for both men and women,…
Abstract Number: 1976 • 2012 ACR/ARHP Annual Meeting
Treatment Satisfaction in Postmenopausal Women Previously Treated with Bisphosphonates Who Transitioned to Denosumab Vs Ibandronate Therapy in an Open-Label Study
Santiago Palacios¹, Giovanni Iolascon², Irene Agodoa³, Hema Viswanathan³, Prayashi Ghelani⁴, Irene Ferreira⁵, Cynthia O'Malley⁶, Rachel B. Wagman⁷ and Sydney Bonnick⁸, ¹Instituto Palacios, Madrid, Spain, ²Seconda Universita di Napoli, Naples, Italy, ³Amgen Inc, Thousand Oaks, CA, ⁴Ovatech Solutions, London, United Kingdom, ⁵Amgen Inc., Cambridge, United Kingdom, ⁶Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Clinical Research Center of North Texas, Denton, TX
Background/Purpose: Higher treatment satisfaction is associated with greater persistence with osteoporosis therapy in postmenopausal women (Barrett-Connor OI 2012). Greater satisfaction has been reported with subcutaneous…
Abstract Number: 1977 • 2012 ACR/ARHP Annual Meeting
Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo
Eric Orwoll¹, Ugis Gruntmanis², Steven Boonen³, Yu-Ching Yang⁴, Rachel B. Wagman⁴, Jesse W. Hall⁴ and Paul D. Miller⁵, ¹Oregon Health and Science University, Portland, OR, ²Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Leuven University, Leuven, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Denosumab, a fully human monoclonal antibody to RANKL, has been shown to increase bone mineral density (BMD) in postmenopausal women with high or low…
Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Amy H. Warriner¹, Ryan C. Outman², Nathan Markward³, Ronald Aubert³, Jeffrey R. Curtis⁴, Robert Epstein³, Felix Freuh³, Julia McEachern³, David T. Redden⁵, Monika M. Safford², Eric Stanek³, Amy Steinkellner³ and Kenneth G. Saag⁶, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medco, Bethesda, MD, ⁴Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
Abstract Number: 1939 • 2012 ACR/ARHP Annual Meeting
Overexpression of Ankyrin Repeat Domain Containing Protein 1 Gene (ANKRD1) in Dermatomyositis Muscle Biopsies Is Correlated to Hypoxia and Perifascicular Atrophy
Samuel K. Shinjo¹, Sueli M. Oba-Shinjo², Miyuki Uno³ and Suely K. N. Marie³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: ANKRD1 codes for ankyrin repeat domain containing protein 1, which belongs to the muscle ankyrin repeat protein family involved in a mechano-signaling pathway that…
Abstract Number: 1940 • 2012 ACR/ARHP Annual Meeting
A Comprehensive Study of Novel Serum Markers of ILD Associated with Inflammatory Myopathies
Fang Chen¹, Xiaoming Shu¹, Xin Lu² and Guochun Wang³, ¹China-Japan Friendship Hospital, Beijing, China, ²Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To investigate and compare the association between serum markers and Interstitial Lung Disease (ILD) in patients with inflammatory myopathies(IIM). Methods: Serum levels of KL-6,…
Abstract Number: 1941 • 2012 ACR/ARHP Annual Meeting
Clinical Evaluation of Anti-Aminoacyl tRNA Synthetase Antibodies in Japanese Patients with Connective Tissue Diseases
Masakazu Matsushita, Toshio Kawamoto, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-Jo-1 antibody is an autoantibody specifically detected in sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen corresponding to this autoantibody is histidyl-tRNA synthase, being…
Abstract Number: 1942 • 2012 ACR/ARHP Annual Meeting
Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 17 Years After Diagnosis; Associations with Disease Activity, Duration and Organ Damage
Helga Sanner¹, Thomas Schwartz², Berit Flatø¹, Maria Vistnes², Geir Christensen² and Ivar Sjaastad³, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, ³Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathic disease of childhood affecting skeletal muscle, skin and other organs. Increased abundance of pro-inflammatory cytokines has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].